患者参与和招聘解决方案指南

Table of Contents About the guide Market challenges04 Benefits of a patient engagement and recruitment solution06 Patient engagement and recruitment solutionfeatures to look for07 How the ideal patient engagement and recruitment solutioncan transform your recruitment campaign09 Citeline PatientMatch: for precision in patient recruitment10 Backed by experts11 About the guide Clinical trials have grown in complexity over the past decades, making it exceedingly difficult to recruitpatients. An estimated 86% of clinical trials do not meet their initial patient enrollment target and timeline,and close to one-third of all Phase III trials fail because of enrollment problems.1Delays caused by under-enrollment can result in lost revenue of as much as $8 million a day for drug developers.2 This guide touches on some of the most common challenges faced in clinical trial patient recruitment and offerstips on how to best address them by employing a patient engagement and recruitment solution. A Guide to Patient Engagement and Recruitment Solutions Market challenges As much as clinical trials have changed over the years, one thing remains constant: the battle to recruitparticipants. Sponsors and sites face many challenges in patient recruitment, but some of the more critical are… Lack of patient awareness of trialopportunities Failure to reach diverse patient populations In recent years, especially in light of the US Foodand Drug Administration (FDA) guidance mandatingDiversity Action Plans for certain clinical trials,sponsors have increased efforts to seek out hard-to-reach patient populations. However, there is muchroom for progress. The good news is patient awareness of clinical trialopportunities appears to have improved. Accordingto the Center for Information and Study on ClinicalResearch Participation (CISCRP), 52% of respondentsto its 2025 Perceptions & Insights Study who havenever participated in a clinical trial remember havingseen or heard about a clinical research study thatwas seeking volunteers in the past six months.3 According to the FDA’s Center for Drug Evaluationand Research (CDER), white patients comprised morethan 50% of the trial population enrolled for all butthree of the 50 novel therapies approved in 2024.4That means 95% of approved drugs for the year hada majority white trial patient population. Still, that leaves 48% who do not recall seeing orhearing of any ongoing studies. This strongly indicatessponsors and sites are not reaching all potential trialcandidates with their current recruitment efforts. Diversity covers a wide range of demographics,including racial and ethnic minority, gender,LGBTQIA+, age, and disability. Overly restrictiveinclusion/exclusion (I/E) criteria could summarilypreclude individuals in underrepresented groupsfrom participating in clinical trials. Failure to includediverse patients in a clinical trial can negativelyaffect the quality of the study and lessen the validityof its results.1 Limited recruitment pools When it comes to patient recruitment, siteinvestigators often start with their own databaseto source and prescreen potential clinical trialcandidates. This can be limiting in terms of size,recruitment area, therapeutic focus, and whether thedata records in question are up to date. According to CISCRP’s Perception & Insights study,39% of respondents who have never participatedin a clinical trial prefer to hear about these trialsonline, and 50% of those respondents prefer to hearabout them through social media.3Yet when goingbeyond their own databases, sites tend to use moretraditional advertising methods for recruitment,which may not reach all available patients. Sitessometimes avoid advertising on social media andsearch engines due to a lack of expertise andexperience with the regulations involved. Site burden Sites frequently face numerous challenges in patientrecruitment and enrollment. For instance, it can betough for sites to find candidates who fit all thecriteria in a complex clinical trial protocol. Given they are often managing multiple studiesat once, sites may have inadequate staffing andoperational inefficiencies that prevent them fromclosely tracking and reporting recruitment efforts. Theuse of multiple software platforms and formats canalso make it hard to monitor recruitment activities. Competition is another limiting factor. A siterecruiting for a study may be competing for thesame patients with sites running similar studies in thesame region. This is especially true for rare diseases,which have an inherently limited patient population. Missed patient follow-up A potential trial candidate can drop off the radarat multiple points along the recruitment journey.The patient may not receive a phone call or email,or may be unable to visit the site for a screening.Overburdened sites may lack the staff or resourcesto follow up at every point on the continuum and thusmiss an enrollment opportunity. Lack of visibility into recru